Seth M. Steinberg

87.2k total citations · 13 hit papers
864 papers, 58.9k citations indexed

About

Seth M. Steinberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Seth M. Steinberg has authored 864 papers receiving a total of 58.9k indexed citations (citations by other indexed papers that have themselves been cited), including 409 papers in Oncology, 240 papers in Pulmonary and Respiratory Medicine and 148 papers in Immunology. Recurrent topics in Seth M. Steinberg's work include Lymphoma Diagnosis and Treatment (118 papers), Immunotherapy and Immune Responses (79 papers) and Cancer Immunotherapy and Biomarkers (73 papers). Seth M. Steinberg is often cited by papers focused on Lymphoma Diagnosis and Treatment (118 papers), Immunotherapy and Immune Responses (79 papers) and Cancer Immunotherapy and Biomarkers (73 papers). Seth M. Steinberg collaborates with scholars based in United States, Italy and Malaysia. Seth M. Steinberg's co-authors include Steven A. Rosenberg, James Chih‐Hsin Yang, Richard M. Sherry, Suzanne L. Topalian, David J. Liewehr, Donald E. White, Douglas J. Schwartzentruber, William D. Figg, Elise C. Kohn and Elaine S. Jaffe and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Seth M. Steinberg

854 papers receiving 57.3k citations

Hit Papers

Use of proteomic patterns in serum to identify ovaria... 1987 2026 2000 2013 2002 2014 2003 2011 2003 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of proteomic patterns in serum to identify ovarian cancer
    2002 2.4k citations Seth M. Steinberg, Elise C. Kohn et al. profile →
  2. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
    2014 2.2k citations Maryalice Stetler‐Stevenson, Marianna Sabatino et al. profile →
  3. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
    2003 2.1k citations James Chih‐Hsin Yang, Leah Haworth et al. profile →
  4. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
    2011 1.6k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. Clinical Cancer Research profile →
  5. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
  6. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
    1998 1.1k citations Suzanne L. Topalian, Eli Glatstein et al. profile →
  7. Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy
    1995 866 citations Crystal L. Mackall, Clara C. Chen et al. profile →
  8. Ten-Year Results of a Comparison of Conservation with Mastectomy in the Treatment of Stage I and II Breast Cancer
    1995 683 citations Kenneth H. Cowan, Teresa D'Angelo et al. profile →
  9. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
    2003 573 citations James Chih‐Hsin Yang, Richard M. Sherry et al. profile →
  10. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
    2009 561 citations William D. Figg, Seth M. Steinberg et al. profile →
  11. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
    2007 519 citations James Chih‐Hsin Yang, Richard M. Sherry et al. Clinical Cancer Research profile →
  12. A Prospective Randomized Trial of Regional Versus Systemic Continuous 5-Fluorodeoxyuridine Chemotherapy in the Treatment of Colorectal Liver Metastases
    1987 440 citations Seth M. Steinberg et al. profile →
  13. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
    2021 200 citations Constance M. Yuan, Seth M. Steinberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seth M. Steinberg United States 124 29.1k 15.6k 13.6k 12.8k 8.1k 864 58.9k
Razelle Kurzrock United States 119 24.9k 0.9× 21.0k 1.3× 12.3k 0.9× 8.2k 0.6× 10.0k 1.2× 1.2k 60.4k
Adi F. Gazdar United States 132 28.3k 1.0× 36.4k 2.3× 19.3k 1.4× 7.6k 0.6× 4.9k 0.6× 654 70.7k
Carlos Cordon‐Cardo United States 129 22.8k 0.8× 41.4k 2.6× 11.0k 0.8× 7.1k 0.6× 4.2k 0.5× 564 68.1k
Elisabeth G.E. de Vries Netherlands 102 24.1k 0.8× 14.3k 0.9× 7.4k 0.5× 4.3k 0.3× 3.4k 0.4× 1.0k 47.8k
John D. Minna United States 140 26.3k 0.9× 42.2k 2.7× 14.7k 1.1× 8.8k 0.7× 4.8k 0.6× 803 73.8k
Jedd D. Wolchok United States 119 45.3k 1.6× 16.2k 1.0× 11.0k 0.8× 29.7k 2.3× 2.6k 0.3× 568 65.0k
Hagop M. Kantarjian United States 171 28.5k 1.0× 44.3k 2.8× 7.3k 0.5× 13.8k 1.1× 18.9k 2.4× 3.4k 147.9k
Matt van de Rijn United States 86 19.3k 0.7× 23.4k 1.5× 9.7k 0.7× 4.7k 0.4× 6.0k 0.7× 251 50.2k
Donna Neuberg United States 113 14.0k 0.5× 14.4k 0.9× 4.1k 0.3× 9.5k 0.7× 11.3k 1.4× 719 46.3k
Ralph R. Weichselbaum United States 107 18.7k 0.6× 17.9k 1.1× 10.6k 0.8× 9.4k 0.7× 1.8k 0.2× 707 48.4k

Countries citing papers authored by Seth M. Steinberg

Since Specialization
Citations

This map shows the geographic impact of Seth M. Steinberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth M. Steinberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth M. Steinberg more than expected).

Fields of papers citing papers by Seth M. Steinberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seth M. Steinberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth M. Steinberg. The network helps show where Seth M. Steinberg may publish in the future.

Co-authorship network of co-authors of Seth M. Steinberg

This figure shows the co-authorship network connecting the top 25 collaborators of Seth M. Steinberg. A scholar is included among the top collaborators of Seth M. Steinberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seth M. Steinberg. Seth M. Steinberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peer, Cody J., Xianyu Zhang, Hyoyoung Choo‐Wosoba, et al.. (2024). Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers. Frontiers in Oncology. 14. 1386190–1386190. 3 indexed citations
2.
Holtzman, Noa G., Rachel B. Salit, Brian C. Shaffer, et al.. (2024). High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Advances. 8(16). 4294–4310. 4 indexed citations
3.
Steinberg, Seth M., et al.. (2024). National Institutes of Health Funding for Surgeon-Scientists in the US—An Update and an Expanded Landscape. JAMA Surgery. 159(3). 323–323. 4 indexed citations
4.
Cohen, Julia W., Brigitte C. Widemann, Joanne Derdak, et al.. (2019). Cediranib phase‐II study in children with metastatic alveolar soft‐part sarcoma (ASPS). Pediatric Blood & Cancer. 66(12). e27987–e27987. 11 indexed citations
5.
Alewine, Christine, Cody J. Peer, Zishuo I. Hu, et al.. (2019). Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research. 26(4). 828–836. 40 indexed citations
6.
Ramaswami, Ramya, Thomas S. Uldrick, Mark N. Polizzotto, et al.. (2019). A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. Clinical Cancer Research. 25(14). 4238–4247. 23 indexed citations
7.
Khanna, Swati, Francis Mussai, Anish Thomas, et al.. (2018). Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clinical Cancer Research. 24(12). 2859–2872. 43 indexed citations
8.
Kraft, Ira L., Srivandana Akshintala, Haiyan Lei, et al.. (2017). Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research. 24(4). 753–765. 20 indexed citations
9.
Duffy, Austin G., Chi Ma, Susanna V. Ulahannan, et al.. (2017). Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research. 23(16). 4633–4641. 68 indexed citations
10.
Merchant, Melinda S., Donna Bernstein, Kristin Baird, et al.. (2016). Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. Clinical Cancer Research. 22(13). 3182–3191. 87 indexed citations
11.
Bartlett, Edmund K., Patricia Fetsch, Armando Filie, et al.. (2014). Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration. Clinical Cancer Research. 20(10). 2607–2616. 21 indexed citations
12.
Fox, Elizabeth, Brigitte C. Widemann, Meredith K. Chuk, et al.. (2013). Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Clinical Cancer Research. 19(15). 4239–4248. 110 indexed citations
13.
Kelly, Ronan J., Arun Rajan, Jeremy Force, et al.. (2011). Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research. 17(5). 1190–1199. 58 indexed citations
14.
Annunziata, Christina M., Amanda J. Walker, Lori M. Minasian, et al.. (2010). Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2. Clinical Cancer Research. 16(2). 664–672. 69 indexed citations
15.
Gril, Brunilde, Dario Palmieri, Julie L. Bronder, et al.. (2008). Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI Journal of the National Cancer Institute. 100(15). 1092–1103. 218 indexed citations
16.
Madan, Ravi A., James L. Gulley, Jeffrey Schlom, et al.. (2008). Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy. Clinical Cancer Research. 14(14). 4526–4531. 119 indexed citations
17.
Dahut, William L., Charity D. Scripture, Edwin M. Posadas, et al.. (2008). A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Clinical Cancer Research. 14(1). 209–214. 142 indexed citations
18.
Toro, Jorge R., Stephen E. Pautler, Laveta Stewart, et al.. (2007). Lung Cysts, Spontaneous Pneumothorax, and Genetic Associations in 89 Families with Birt-Hogg-Dubé Syndrome. American Journal of Respiratory and Critical Care Medicine. 175(10). 1044–1053. 232 indexed citations
19.
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377. 1234 indexed citations breakdown →
20.
Pierce, Lori J., Maria J. Merino, Teresa D'Angelo, et al.. (1994). Is C-ERB B-2 a predictor for recurrent disease in early stage breast cancer?. International Journal of Radiation Oncology*Biology*Physics. 28(2). 395–403. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Adi F. Gazdar Breakdown of academic impact, for papers by Carlos Cordon‐Cardo Breakdown of academic impact, for papers by Elisabeth G.E. de Vries Breakdown of academic impact, for papers by John D. Minna Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by Hagop M. Kantarjian Breakdown of academic impact, for papers by Matt van de Rijn Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by Ralph R. Weichselbaum
Rankless by CCL
2026